Other
Staphylococcus Aureus Bacteremia
0
Pipeline Programs↗
5
Active Trials↗
6
Companies Involved↗
Staphylococcus Aureus Bacteremia is an early-stage landscape with 0 programs across 6 companies. The most active players are Basilea Pharmaceutica, Bristol-Myers Squibb, Cumberland Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed11 · 61%
Not yet recruiting2 · 11%
Unknown status1 · 6%
Withdrawn1 · 6%
Recruiting1 · 6%
Enrolling by invitation1 · 6%
Other1 · 6%
Clinical Trials
Trial Activity
18 trials
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Recruiting·—·Phase 2·NCT04886284·60 enrolled
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Active, not recruiting·—·N/A·NCT07186894·5,000 enrolled
Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
Not yet recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT07384702·230 enrolled
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT02972983·102 enrolled
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04775953·200 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)